Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2 inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety and tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal carcinoma. AP 12009, administered intravenously, showed a clear proof of concept. Patients with stage IV pancreatic carcinoma, who received AP 12009 for seven days every other week as second or third line therapy, had a median survival time of 29.6 weeks (6.8 months) after start of AP 12009 treatment. One of these patients with several liver metastases even experienced a complete response. Efficacy and safety results of the multicenter Phase I/II study were published today at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA (1).

In the open-label, multicenter, dose-escalation Phase I/II study patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal carcinoma were included. So far 25 patients have been treated in six cohorts. The first four cohorts received AP 12009 as 7-day on, 7-day off cycles. For this schedule, the maximum tolerated dose (MTD) was reached with two grade III thrombocytopenias as dose-limiting toxicities (DLT). These were self-limiting and required no therapeutic intervention. The third DLT was a grade III rash. Thus, the compound AP 12009 revealed excellent safety and tolerability. Very encouraging case reports were observed. One patient, diagnosed with stage IV malignant melanoma, survived more than 60 weeks after the start of AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had a complete response and is still alive as of March 2008 148 weeks (34 months) after the start of treatment with AP 12009.

After reaching the MTD with the 7-day on, 7-day off schedule, a second schedule with 4-day on, 10-day off cycles was initiated. Two cohorts with a total of seven patients h
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...ndings offer hope for increased life expectancy fo.../PRNewswire-USNewswire/ -- In the world of Down,sy...rogress has been,tracked for the past 16 years, at...ife expectancy of a person with Down syndrome, cur...,Mr. C, was born. Further, ,Mr. C, does,not exhibi...
(Date:8/18/2008)...Leader with Strong Clinical Research Relationships...nizations to Lead Commercialization, SANTA CLARA,...io, Inc.,(OTC Bulletin Board: NWCI) a cardiac dia... Vincent W. Renz has joined NewCardio as its presi...alization effort, to include,business development,...
(Date:8/17/2008)...Australia, Aug. 17 /Xinhua-...ed that the first pivotal Phase 3,clinical trial o...has,completed enrolment., The first efficacy data... the first half of 2009. The trial commenced its d...ruitment target of 250 subjects in June,2008 and c...
(Date:8/14/2008)... A Complimentary Continuing Education Activity, ...ovirus (CMV) is a,significant cause of morbidity a...ell transplantation. The clinical manifestations o...estinal disease to life-threatening,pneumonia, mye...rder to prevent CMV infection and reduce CMV drug ...
Breaking Medicine Technology:Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 1Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 2Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 3Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 4Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 5HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 1HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 2HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 3HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 4IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 1IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 2IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 3IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 4IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 5IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 6IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 7Biopure Launches Updated Website 2955 1Biopure Launches Updated Website 2955 2
...gium, March 28, 2007,/PRNewswire-FirstCall/ -- Bio...lts of a sample collection study aimed at,identify...n the,assessment for risk of sepsis progression. S...rapeutic options. Clinical investigator,Emanuel P...,research at the department of emergency medicine ...
...e World,s First Commercial Vaccine,for Travellers,...mpletes Phase I Clinical Trials , ,Trial confirms ...ENSE, Denmark, March 28, 2007 -ACE BioSciences A/S...nounce the successful,completion of Phase I clinic...,s first commercial vaccine for Travellers,Diarrh...
Other Medicine Technology:Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 2Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 3Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 4Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 5Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4
(Date:8/20/2008)...n, adult females, but not in men, study finds , ...lcoholism is associated with delayed childbearing ...,s and men,s lifetime history of alcohol dependenc..., The researchers analyzed data from two groups... female and 1,880 male twins) and between 1964-19...
(Date:8/20/2008)...e/ -- WXYZ- TV/Channel 7 and The,Detroit Departmen...ands of,Detroit metro area children a "boost" at t...This year the program will be held Sunday, August ...Wright Museum of African,American History. Since i...s provided free immunizations to over 50,000 young...
(Date:8/20/2008)...swire-FirstCall/ -- Tianyin,Pharmaceutical, Co., I...rer,and supplier of modernized traditional Chinese...nnounced that the Company,s stock symbol had been,...electronic eligibility,system error., The error i...cts the,stock symbol to trade under the symbol OTC...
(Date:8/20/2008)...urteen physicians who have been,part of Commonweal...enhance,the care and service they provide to their...are top-notch primary care physicians, and we are ...on," said Nick Turkal, M.D., Aurora,s,president an...king with,them to support their care of patients i...
Breaking Medicine News(10 mins):Health News:Women's Alcohol Use Tied to Delayed Childbearing 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2
...ho have implanted devices in their hearts face ris...ake arteries patent or open to allow an easy passa...s by surgeons.Stents may be medicated or non medic...o suffer from internal blood clotting. The risk is...
...keenly studied the effect of discontinuing HIV dru...red. The results can be positively// devastating, ...e has published the results of this current resear...ntinued, the patients face a greater chance of dev...
...s that are used in treatment of cancer, are likely...y a research, published by the Journal of Biology.... in brain damage. The effects may be long lasting....enon termed 'chemobrain'.Chemobrain refers to the ...
...e to consume junk food which is over laden with sa...f traditional home made food. This has resulted in...er concentration of salt as their salt receptors a...s like childhood hypertension and early developmen...
Other Medicine News:Health News:Using Heart Stents Tends to Form More Clots 2Health News:Interrupted Treatment Dangerous to HIV Management 2
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
Utilizing breakthrough electro-optical and rotary prism technology, the new RM-8000B SUPRA is capable of obtaining perfectly accurate refraction measurements through pupils as narrow as 2.0mm. This m
Sterile free isotonic balanced salt solution
Sterile perfluorocarbon for intraocular Application.
Medicine Products: